DMD Voice: Qualitative Interviews With Patients and Caregivers
Launched by RED NUCLEUS ENTERPRISE SOLUTIONS, LLC · Apr 10, 2025
Trial Information
Current as of September 05, 2025
Recruiting
Keywords
ClinConnect Summary
The DMD Voice study is a research project aimed at understanding how Duchenne Muscular Dystrophy (DMD) affects the daily lives of boys with the condition and their caregivers. Through one-on-one interviews lasting about 60 minutes, participants will share their experiences regarding functional abilities, independence, and quality of life. This study does not involve any treatments or medications; instead, it focuses on gathering valuable insights from those directly impacted by DMD.
To take part in this study, boys with DMD must be at least 10 years old and have been receiving a specific treatment called Givinostat for at least two years. Their caregivers can also join if they are parents or legal guardians of these boys. Another group of caregivers who take care of boys with DMD who have limited mobility can participate as well. Participants should be comfortable with video or audio recording, able to communicate in English, and have a stable internet connection for the interviews. This study is currently recruiting and aims to give a voice to those living with DMD to better understand their needs and experiences.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Subsample A - Patients
- Eligible participants for Subsample A must:
- • Have been treated with Givinostat for at least 2 years
- • Be at least 10 years of age with signed consent of a parent or legal guardian
- • Be currently taking givinostat
- • Willing and able to participate in a video and/or audio recorded interview
- • Subsample A - Caregivers
- Eligible caregivers for Subsample A must:
- • Be a parent or legal guardian of an individual with DMD that has been taking givinostat for at least two years
- • Willing and able to participate in a video and/or audio recorded interview
- • Subsample B - Caregivers
- Eligible caregivers for Subsample B must:
- • Provide care to an individual with DMD who is unable to raise their hands above their head as confirmed by the caregiver
- • Reside in the United States or Canada
- • Able to read, speak, and understand English
- • Willing and able to participate in a video and/or audio recorded interview Have access to a stable internet connection
- Exclusion Criteria:
- • -
About Red Nucleus Enterprise Solutions, Llc
Red Nucleus Enterprise Solutions, LLC is a leading provider of innovative clinical trial management solutions that empower biopharmaceutical companies to streamline their research processes. With a focus on enhancing operational efficiency and data integrity, Red Nucleus offers a comprehensive suite of services, including strategic planning, data analytics, and technology integration. Their expert team works collaboratively with clients to optimize trial design, improve patient engagement, and accelerate time-to-market for new therapies. Committed to advancing healthcare through cutting-edge solutions, Red Nucleus is dedicated to supporting the success of clinical research initiatives across diverse therapeutic areas.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Yardley, Pennsylvania, United States
Patients applied
Trial Officials
Mindy Leffler, M.Ed.
Principal Investigator
Red Nucleus Solutions
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported